- DuoBody-ADC research collaboration with undisclosed pharma company

Copenhagen, Denmark; December 20, 2011 – Genmab A/S (OMX: GEN) announced today that the company has entered a research collaboration with an as yet undisclosed, new large pharmaceutical partner to investigate a bispecific antibody-drug conjugate using Genmab’s DuoBody technology in combination with a novel antibody-drug conjugate technology platform from the pharma company. If successful, the parties may decide to enter into a license agreement to further develop a new DuoBody-ADC product. The target in the collaboration is clinically validated and expressed on solid tumors.

“This research collaboration with a large pharma company marks a first step in our strategy to sign different types of partnership based on our innovative bispecific antibody technology. This partnership will help us to investigate the use of our DuoBody platform in creating more effective treatments for cancer,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

This agreement will not have a material impact on Genmab’s 2011 financial guidance.

About the DuoBody platform
Genmab’s proprietary DuoBody platform creates human bispecific antibodies which bind to two different epitopes, on the same or different disease targets. Bispecific antibodies have the potential to be more potent and efficacious than other antibody therapeutics due to this increased specificity. The DuoBody technology platform uses a natural process to create bispecific antibodies which are ready for therapeutic application without recloning into a therapeutic format. In addition, any antibody sequence can be applied and combined for the generation of new bispecific antibodies via the DuoBody platform. Large scale manufacturing of DuoBody molecules is based on scalable processes. Bispecific antibodies created using the DuoBody platform have possible application in oncology, autoimmune, central nervous system, and infectious diseases.



Company Announcement no. 37
CVR no. 2102 3884

Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark